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Cisplatin-Based Combination Chemotherapy for Advanced
Hepatocellular Carcinoma: A Single Center Experience
before the Sorafenib Era
Introduction
Patients with unresectable or metastatic hepatocellular carcinoma
(HCC), who are not candidates for local/regional treatment, have a
very limited number of therapeutic options (1). To date, sorafenib is the
only systemic therapy proven to prolong overall survival in patients
with advanced HCC who are not candidates for surgical or local/re-
gional therapies. However, the median survival achieved with sora-
fenib therapy was reported to be only 10.7 months compared with
7.9 months in the placebo arm (hazard ratio [HR], 0.69; 95% con-
fidence interval [CI], 0.55 to 0.87; p＜0.001), and was even shorter
in Asian patients (6.2 vs. 4.1 months; HR, 0.67; 95% CI, 0.49 to
0.93; p=0.0155) (2,3).
For those patients who are not candidates for sorafenib treatment
or for those who have had treatment failures after sorafenib, the only
therapeutic option is systemic chemotherapy. However, there are no
standard chemotherapy regimens that have been shown to improve
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Purpose
Systemic chemotherapy is the only option for patients with unresectable/metastatic hepato-
cellular carcinoma (HCC) who are not candidates for local/regional treatment. However, the
response to such treatment and survival are poor, especially in hepatitis B virus (HBV) endemic
areas. The aim of this study was to determine the efficacy of cisplatin-based combination
chemotherapy and identify a subgroup of advanced HCC patients with favorable responses. 
Materials and Methods
The medical records of all consecutive patients with unresectable/metastatic HCC who re-
ceived cisplatin-based combination chemotherapy between January 2003 and October 2009
were reviewed. Time to progression (TTP) and overall survival (OS) were determined using
Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify
prognostic factors for TTP and OS.
Results 
Data for 46 patients were analyzed. First-line chemotherapies consisted of cisplatin-based
combination treatment with doxorubicin, fluoropyrimidines and gemcitabine. The response
rate for all patients was 4.3%. The median TTP and OS were 1.8 (95%confidence interval [CI],
1.1 to 2.5) and 7.2 (95% CI, 3.0 to 11.5) months, respectively. Eastern Cooperative Oncology
Group (ECOG) performance status (PS), Child classification, Cancer of the Liver Italian Program
(CLIP) score and portal vein thrombosis (PVT) were identified by univariate analyses as pro-
gnostic factors for TTP and OS. ECOG PS (hazard ratio [HR], 4.51; 95%CI, 1.61 to 12.6; p=0.004)
and PVT (HR, 2.12; 95%CI, 1.10 to 4.11; p=0.026) were independent prognostic factors for TTP. 
Conclusion 
Cisplatin-based combination chemotherapy in patients with advanced HCC has a low res-
ponse rate and short TTP regardless of the chemotherapy regimen used. Patients with a good
ECOG PS and without PVT can be considered candidates for cisplatin-based combination
chemotherapy. 
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Open Accessoverall survival. A large number of controlled and uncontrolled studies
have been performed with most of the major classes of chemotherapy
agents given as single or combination therapies. Single or combi-
nation regimens of other drugs, including doxorubicin, 5-fluorouracil
(5-FU), capecitabine, cisplatin, gemcitabine, and mitoxantrone have
elicited 0% to 27% response rates, 2 to 6 months time to progression
(TTP) or progression-free survival, and 3 to 12 months of overall
survival (OS) (4-9). 
The most widely studied regimens in patients with advanced HCC
are doxorubicin and cisplatin-based chemotherapies. Doxorubicin
was associated with a single agent response rate of 0-15% (4,10).
Doxorubicin as a single agent, when compared to the combination
of cisplatin, interferon, doxorubicin, and 5-FU (PIAF) in a phase III
randomized trial, caused a lower response rate (10.5% vs. 20.9%)
but a similar OS rate (6.83 vs. 8.67 months, p=0.83). Doxorubicin
single agent used to be considered a standard treatment for patients
with advanced HCC before the sorafenib era (11). Cisplatin-based
combination regimens were reported in some studies to result in
higher objective response rates than regimens excluding cisplatin.
Cisplatin administration had an objective response rate of 15% as
single-agent chemotherapy, and a higher response rate when combi-
ned with doxorubicin, 5-FU and gemcitabine (5-9,11,12). However,
there are insufficient data to recommend any one regimen as the
standard of care. 
Systemic chemotherapy loses efficacy due to the frequently ob-
served development of multidrug tumor resistance, which is related
to the high rate of expression of the multidrug resistance gene (MDR1),
and p53 tumor suppressor gene mutations (13,14). Poor hepatic
function in patients with advanced HCC results in higher toxicity
and precludes systemic chemotherapy in many patients. Therefore,
patient selection for those who would benefit from systemic chemo-
therapy is of vital importance before initiating systemic chemo-
therapy in patients with advanced HCC. 
The aim of this study was to determine the efficacy of cisplatin-
based combination chemotherapy and identify a subgroup of patients
with advanced HCC who would be candidates for cisplatin-based
combination chemotherapy. The records of all consecutive patients
with advanced HCC who received cisplatin-based combination che-
motherapy at a single center, before the sorafenib era, were retro-
spectively analyzed by univariate and multivariate prognostic factor
analyses.
Materials and Methods
1 Patients
Between January 2003 and October 2009, consecutive patients
with unresectable or metastatic HCC who received cisplatin-based
combination as the first-line chemotherapy at Seoul National Uni-
versity Bundang Hospital were retrospectively enrolled. Patients had
disease progression after a curative resection or other local treatment
procedures, such as radiofrequency ablation (RFA), cryoablation or
transarterial chemoembolization (TACE), or were not amenable to
local/regional treatment. The diagnosis of HCC was confirmed by
histopathology or by computed tomography (CT), magnetic resonance
imaging (MRI), and angiographic findings in addition to elevated
values of alpha-fetoprotein (AFP) using the guidelines proposed by
the Korea Liver Cancer Study Group (15). Using these criteria, a pa-
tient was diagnosed with HCC if one or more risk factors (hepatitis
B virus [HBV] or hepatitis C virus [HCV] infection, or cirrhosis)
were present, and one of the following was also present: a serum
AFP level＞400 ng/mL and a positive result on at least one of the
three typical liver imaging techniques (spiral CT, contrast enhanced
dynamic MRI or hepatic angiography); or a serum AFP level＜400
ng/mL and positive findings on at least two of the three imaging
techniques. A positive finding for typical HCC with dynamic CT or
MRI is indicative of arterial enhancement followed by venous
washout in the delayed portal/venous phase. TNM stages were used
for tumor staging and clinical stages were classified according to the
Cancer of the Liver Italian Program (CLIP) staging system (16,17).
2 Cisplatin-based combination chemotherapy
The first-line chemotherapy regimens given to patients were
cisplatin-based combination chemotherapy with doxorubicin (AP),
5-FU (FP), capecitabine (XP) and gemcitabine (GP). The AP regimen
consisted of doxorubicin 60 mg/m
2 delivered as an intravenous in-
fusion over 30 minutes on day 1, followed by cisplatin 60 mg/m
2 in-
fused over 30 minutes on day 1. The FP regimen consisted of 5-FU
1,200 mg/m
2 administered continuously on days 1 to 4, and cisplatin
60 mg/m
2 infused over 30 minutes on day 1. The XP regimen con-
sisted of capecitabine 2,000 mg/m
2 orally administered on days 1 to
14, and cisplatin 60 mg/m
2 infused over 30 minutes on day 1. The
GP regimen consisted of gemcitabine 1,200 mg/m
2 infused on days
1 and 8, and cisplatin 60 mg/m
2 infused over 30 minutes on day 1.
Chemotherapy cycles were repeated every 21 days until disease
progression or intolerable toxicity.
3 Response and toxicity evaluation
Response was assessed after every two cycles of chemotherapy
by CT or MRI scan using the Response Evaluation Criteria in Solid
Tumors (RECIST) criteria (18). Complete response (CR) was defined
as the disappearance of all target and non-target lesions compared to
baseline. Partial response (PR) was defined as at least a 30% de-
crease in the sum of the longest diameters of all target lesions, taking
as a reference the baseline sum of the diameters with no new lesions
appearing. Patients were considered to have progressive disease (PD)
if any new lesion appeared, if the tumor size increased by at least
20% in the sum of the diameters of the target lesions, taking as re-
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ference the smallest sum on study, or if there was unequivocal pro-
gression of existing non-target lesions. A patient who failed to meet
the definition of CR, PR or PD was classified as having stable disease
(SD). The percentage of patients who had the best responses (other
than PD) according to the RECIST criteria, and had those responses
maintained for at least 28 days after the first radiologic evaluation,
was defined as the disease control rate. Toxic effects of chemotherapy
were evaluated according to the National Cancer Institute-Common
Terminology Criteria for Adverse Events version 3.0.
4 Statistical analysis
The TTP was calculated from the first day of chemotherapy to the
day when progressive disease was documented. OS (in days) was
calculated from the first day of chemotherapy to death by any cause.
All survival distributions were calculated using the Kaplan-Meier
method and the log-rank test was used for univariate analysis. The
Cox proportional hazard model was used to assess the prognostic
factors by multivariate analysis. All analyses were done using SPSS
ver. 15.0 (SPSS Inc., Chicago, IL) and a p≤0.05 was considered
statistically significant. The study was approved by an independent
review board at the Seoul National University Bundang Hospital
(IRB approval number: B-1003-095-102). 
Results   
1 Patient characteristics
Between January 2003 and October 2009, 73 patients received
systemic chemotherapy at Seoul National University Bundang Hos-
pital. Among the 73, we identified 46 who underwent cisplatin com-
bination chemotherapy as the first-line chemotherapy. The diagnosis
of HCC was confirmed by pathology in five patients; for the re-
maining 41 patients, the diagnosis was established by CT, MRI, and
angiographic findings in addition to elevated values of AFP using the
guidelines proposed by the Korea Liver Cancer Study Group (15). 
A total of 46 patients with HCC were analyzed in this study, and
their clinical characteristics are summarized in Table 1. The mean age
of the patients was 53 years (range, 21 to 73 years) and the male to
female ratio was 4.1 : 1. HBV infection was documented in most of
the patients (82.6%), HCV infection in a few (4.3%) and both infec-
tions in even fewer (2.2%). The majority of patients had an Eastern
Cooperative Oncology Group (ECOG) performance (PS) score of
0-1 (84.8%) with liver function classified as Child-Pugh classifi-
cation A (69.6%). The sites of extrahepatic metastases included lung
in 32 (69.6%), bone in 14 (30.4%) and lymph nodes in 31 (67.4%)
patients. Previous treatments included surgery in 13 patients (28.3%),
TACE in 31 (67.4%), and RFA in six patients (13.0%). An AFP
level higher than 400 ng/mL was recorded in 23 (50.0%) patients,
and 28 patients (60.9%) had portal vein thrombosis. The HBeAg
was positive in 10 patients (25.6% among HBV-positive patients).
Eleven patients (23.9%) had a CLIP score of 0 or 1 points, 23 (50.0%)
patients had 2-3 points, and 12 patients (26.1%) had 4-6 points. 
2 Efficacy 
Patients received a mean of 2.3 cycles of cisplatin-based com-
bination chemotherapy (range, 1 to 6 cycles): 10 patients received
Table 1. Baseline patient characteristics
Characteristics No. (%)
Age ≤60 yr 31 (67.4)
＞60 yr 15 (32.6)
Sex Male 37 (80.4)
Female 9 (19.6)
ECOG*performance status 0-1 39 (84.8)
2 7 (15.2)
Etiology HBV
� 38 (82.6)
HCV
� 2 (4.3)
HBV+HCV 1 (2.2)
Both negative 5 (10.9)
Site of metastases Lung 32 (69.6)
Bone 14 (30.4)
Lymph node 31 (67.4)
Peritoneum 4 (8.7)
Other 1 (2.2)
AJCC
§stage 3C 5 (10.9)
4 41 (89.1)
Tumor morphology Extension≤50% 35 (76.1)
Extension＞50% 11 (23.9)
Child-Pugh classification A 32 (69.6)
B 14 (30.4)
CLIP
‖score 0-1 11 (23.9)
2-3 23 (50.0)
4-6 12 (26.1)
Previous local treatment  Surgery 13 (28.3)
Transarterial chemoembolization 31 (67.4)
Radiofrequency ablation 6 (13.0)
Percutaneous ethanol injection 2 (4.3)
Radiotherapy 17 (37.0)
AFP
¶ ≤400 23 (50.0)
＞400 23 (50.0)
Portal vein thrombosis  Yes 28 (60.9)
No 18 (39.1)
HBeAg + 10 (27.0)
- 27 (73.0)
*Eastern Cooperative Oncology Group , 
�hepatitis B virus, 
�hepatitis C virus, 
§ Ameri-
can Joint Committee on Cancer, 
‖Cancer of the Liver Italian Program, 
¶alpha-feto-
protein.doxorubicin combination (AP); 32 fluoropyrimidine combination (FP
and XP); and 4 patients received gemcitabine combination (GP)
chemotherapy. The best responses to first-line chemotherapy are
shown in Table 2: no complete response was observed; two patients
(4.3%) achieved partial remission; 14 (30.4%) had stable disease; and
30 (65.2%) had progressive disease. The overall response rate was
4.3% and the disease control rate was 34.7%. There were no significant
differences in response rates among the different regimens (p=0.28). 
A total of 19 patients received second-line chemotherapy. A mean
of 2.8 cycles of chemotherapy (range, 1 to 6 cycles) was given. Two
patients received anthracycline-based chemotherapy, 4 fluoropy-
rimidine-based, 10 gemcitabine-based, and 3 patients received sora-
fenib. The response rate was 5.3% (1/19) and the disease control rate
was 47.4% (9/19). 
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Regimen (n) Partial response Stable disease Progressive disease Time to progression  (mo) Overall survival (mo)
Doxorubicin (10) 1 (10.0) 4 (40.0) 5 (50.0) 2.3 8.5
Fluoropyrimidine (32) 1 (3.1) 9 (28.1) 22 (68.8) 1.8 4.1
Gemcitabine (4) 0 (0.0) 1 (25.0) 3 (75.0) 1.9 4.7
All 2 (4.3) 14 (30.4) 30 (65.2) 1.8 5.5
Table 2. Response and survival in patients treated with each cisplatin-based combination
Values are presented as number (%).
Variables Time to progression p-value Overall survival p-value
Age ≤60 yr 2.0 (0.9, 3.1) 0.31 7.4 (3.5, 11.4) 0.88
＞60 yr 1.5 (1.2, 1.8) 4.0 (2.7, 5.3)
Gender Male 1.6 (1.1, 2.1) 0.31 4.5 (0.6, 8.5) 0.25
Female 2.4 (2.1, 2.7) 7.4 (6.8, 8.0)
ECOG PS* 0-1 2.2 (1.7, 2.7) ＜0.001 8.1 (5.5, 10.7) 0.012
2 0.9 (0.5, 1.3) 3.2 (1.5, 7.6)
Etiology HBV
� 1.8 (1.0, 2.6) 0.60 7.2 (3.1, 11.3) 0.77
Non-HBV 1.8 (0.5, 3.1) 8.5 (7.4, 9.5)
Metastasis Lung  0.78 0.97
Yes 1.8 (0.9, 2.8) 4.5 (1.8, 9.0)
No 1.6 (0.7, 2.5) 7.1 (0.6, 13.8)
Bone   0.23 0.21
Yes 1.3 (0.7, 1.8) 4.1 (4.0, 4.2)
No 1.8 (1.3, 2.4) 7.2 (2.5, 11.9)
Lymph node   0.12 0.07
Yes 1.3 (1.0, 1.7) 4.1 (2.8, 5.3)
No 2.4 (1.7, 3.0) 7.5 (3.5, 11.5)
AJCC
�stage 3C 1.3 (1.2, 1.5) 0.85 3.0 (1.4, 4.6) 0.61
4 1.9 (1.1, 2.6) 7.2 (4.5, 10.0)
Tumor morphology Extension ≤50% 2.0 (1.3, 2.7) 0.12 8.5 (5.3, 11.6) 0.13
Extension ＞50% 1.3 (0.9, 1.7) 3.2 (0, 12.9)
Child-Pugh classification A 2.0 (1.1, 2.9) 0.02 8.1 (2.3, 13.8) 0.047
B 1.2 (0.8, 1.6) 2.2 (0, 4.1)
CLIP
§score 0-1 2.4 (1.0, 3.8) 0.012 13.3 (1.9, 24.6) 0.007
2-3 1.8 (0.5, 3.2) 7.6 (2.7, 12.4)
4-6 1.2 (0.9, 1.5) 2.2 (1.6, 2.7)
AFP
‖ ≤400 ng/mL 1.6 (1.0, 2.1) 0.30 7.2 (2.6, 11.9) 0.32
＞400 ng/mL 1.9 (1.0, 2.7) 4.1 (1.7, 6.5)
PVT
¶ Yes 1.3 (1.1, 1.4) 0.003 3.0 (1.5, 4.4) 0.003
No 2.5 (1.9, 3.2) 14.5 (10.0, 18.9)
Table 3. Prognostic factors for time to disease progression and overall survival by univariate analysis
*performance status, 
�hepatitis B virus, hepatitis C virus, 
�American Joint Committee on Cancer, 
§ Cancer of the Liver Italian Program, 
‖alpha-fetoprotein, 
¶portal vein thrombosis.3 Survival analysis
After a median follow-up duration of 5.5 months, the median time
to progression for all patients was 1.8 months (95% CI, 1.1 to 2.5).
There was no statistically significant difference in the time to pro-
gression among the regimens: 2.3 (95% CI, 0.2 to 4.4) months for
the AP regimen, 1.8 months (95% CI, 0.8 to 2.2) for the fluoropy-
rimidine combination (FP, XP) and 1.9 (95% CI, 0.1 to 2.5) months
for the GP regimen. The median OS from the start of chemotherapy
was 7.2 (95% CI, 3.0 to 11.5) months. The overall survival was 8.5
(95% CI, 3.0 to 13.9) months for the AP regimen, 4.1 months (95%
CI, 2.3 to 5.8) for the fluoropyrimidine combination and 4.7 months
(95% CI, cannot be calculated) for the GP regimen (Table 2).
4 Prognostic factors
On univariate analysis, poor ECOG PS, Child classification B
compared to A, high CLIP score, and presence of portal vein throm-
bosis were statistically significant factors that indicated a poor pro-
gnosis for both TTP and OS (Table 3) (Fig. 1). Based on multi-
variate analyses using a model with factors entered for a significance
level of p≤0.05, poor ECOG PS (HR, 4.51; 95% CI, 1.61 to 12.6;
p=0.004) and the presence of portal vein thrombosis (HR, 2.12; 95%
CI, 1.10 to 4.11; p=0.026) were independent poor prognosis factors
for TTP. The presence of portal vein thrombosis (HR, 2.77; 95% CI,
1.36 to 5.62; p=0.005) was the only significant poor prognosis factor
for OS (Table 4).
5 Toxicity
Toxicities were mostly hematologic, with grade 3/4 leukopenia in
six (13%), neutropenia in 14 (30.4%) and thrombocytopenia in five
(10.9%) patients. A Grade 3/4 elevation of the aminotransferases
occurred in 11 (23.9%) patients, and jaundice in eight (17.4%) pa-
tients. There was no significant difference in hematologic and liver-
related toxicities among the cisplatin-based combination (Table 5)
treatment. However, grade 3/4 neutropenia was more frequent in the
GP and AP regimens. There was no treatment-related death.
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Fig. 1. (A) Time to progression according to Eastern Cooperative Oncology Group (ECOG) performance status. (B) Overall survival in patients
with and without portal vein thrombosis (PVT).
Time to progression Overall survival
Variables No. (%)
HR* 95% CI� p-value HR 95% CI p-value
ECOG� 0-1 39 (84.8) 0.004 0.685
2 7 (15.2) 4.51 1.61-12.6 1.24 0.44-3.51
Child-Pugh  A 32 (69.6) 0.40 0.167
classification B 14 (30.4) 1.40 0.64-3.04 1.71 0.80-3.63
PVT§ No 18 (39.1) 0.026 0.005
Yes 28 (60.9) 2.12 1.10-4.11 2.77 1.36-5.62
Table 4. Prognostic factors for time to disease progression and overall survival by multivariate analysis
*hazard ratio, 
�confidence interval, 
�Eastern Cooperative Oncology Group, 
§ portal vein thrombosis.Cancer Res Treat. 2010;42(4):203-209
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Discussion
The results of this study confirmed the poor prognosis and poor
response to cisplatin-based combination chemotherapy among
patients with advanced HCC, who were not amenable to local/-
regional treatment outside of the clinical trial setting. In this study,
cisplatin-based combination chemotherapy regimens had a response
rate of 4.3%, a median TTP of 1.8 (95% CI, 1.1 to 2.5) months, and
a median OS of 7.2 (95% CI, 3.0 to 11.5) months. 
Our results are consistent with earlier studies that investigated the
efficacy of cisplatin-based combination chemotherapy, although the
results of our study are modest compared to prior studies with regard
to TTP. The results of our study might more accurately reflect real
clinical practice, with unselected patients. A high proportion of
patients with metastases (89.1%) and portal vein thrombosis (60.9%)
in this population may also explain the poor response rates. The
combination of gemcitabine with cisplatin was reported to have a
response rate of approximately 20% (7), a TTP of 18 weeks, and a
median OS of 21 weeks. The combination of capecitabine and cis-
platin elicited a response rate of 6.3%, a TTP of 2 months, and a
median OS of 12.2 months (8). 
Although not statistically significant, the AP regimen had a longer
TTP and OS than the other regimens (FP, XP, GP) (Table 2). There
were no differences in clinical characteristics of patients who received
AP compared to the other regimens in this study. Lee et al. (6) re-
ported that the response rate and disease control rate associated with
the AP regimen were 18.9% (7/37) and 35.1% (13/37), respectively,
and the median TTP and OS were 6.6 and 7.3 months. Kang et al.
(12), found that the response rate and disease control rate of the AP
regimen were, respectively, 58.6% (6/21) and 76.2% (46/21), and
the median TTP and OS were, respectively, 5.4 and 10.7 months.
The OS achieved with the AP regimen showed consistency across
trials, 7.3-10.7 months, and compared favorably to the effects of
sorafenib reported in an Asian trial (3). Further study comparing
cisplatin-based combination chemotherapy, especially the AP regimen,
with sorafenib or a combination of cytotoxic regimens with sorafenib
is needed in patients with advanced HCC. 
Based on the results of multivariate analysis, the only independent
prognostic factors in this study population were ECOG PS (p=0.004)
and portal vein thrombosis (p=0.026) with regard to TTP, and portal
vein thrombosis (p=0.005) with regard to OS (Table 4). ECOG PS,
Child-Pugh classification, CLIP score and portal vein thrombosis
were prognostic factors for TTP and OS on univariate analysis.
However, the Child-Pugh classification lost its statistical signi-
ficance in the multivariate analysis, probably due to the small number
of patients enrolled. The CLIP score was not included in the multi-
variate model, since the CLIP score represented a combination of
other risk factors: Child-Pugh stage; tumor morphology and extension;
serum AFP levels; and portal vein thrombosis. 
The overall survival of patients associated with CLIP scores of 0-1,
2-3 and 4-6 were 13.3 (95% CI, 1.9 to 24.6), 7.6 (95% CI, 2.7 to
12.4) and 2.2 (95% CI, 1.6 to 2.7) months, respectively (Table 3).
The median OS of patients in this study was shorter compared to OS
reported in other studies (17,19-22). All patients had disease pro-
gression after a curative resection or other local treatment proce-
dures by enrollment criteria, and the OS was assessed from day one
of chemotherapy, not from the time of diagnosis, which may explain
the short survival duration. However, the decrease in survival asso-
ciated with high CLIP score remained consistent, validating the pro-
gnostic value of CLIP score in this advanced HCC population. 
The results of this study are consistent with the findings of prior
studies regarding prognostic factors (23-25). Leung et al. (23) re-
ported that the prognosis for patients with unresectable HCC after
systemic chemotherapy depended on pre-treatment liver function
and the stage of disease. Portal vein thrombosis causes stenosis or
occlusion of the portal vein; as a result, the blood supply to the liver
parenchyma is decreased and further deterioration of liver function
can occur. Zhang et al. (24) reported that portal vein thrombosis was
often associated with a poor prognosis, and suggested palliative 3-
dimensional conformal radiotherapy, targeting the main portal vein
thrombosis. Tan et al. (25) analyzed clinical prognostic factors in 397
untreated patients with HCC and found that poor performance status,
presence of ascites, and high AFP levels were statistically significant
prognostic factors associated with decreased overall survival.
If the prognostic factors associated with TTP identified in our
study were used to select candidates for cisplatin-based combination
chemotherapy (ECOG PS 0-1 vs. 2, and presence of PVT), the
patients who had no risk factors (ECOG PS 0-1 without PVT)
would have shown a statistically significant increase in TTP compared
to patients with 1 or 2 poor prognostic factors (3.1 [95% CI, 1.8 to
4.3] vs. 1.3 [95% CI, 1.3 to 1.4] vs. 0.7 [95% CI, 0.5 to 0.9] months,
p＜0.0001) and also in OS (14.5 [95% CI, 10.5 to 18.5] vs. 4.5
[95% CI, 0.0 to 9.8] vs. 2.2 (1.1 to 3.2) months, p＜0.0001). These
results suggest that patient selection based on the prognostic factors
described above could aid in selecting candidates who would benefit
from cisplatin-based combination chemotherapy. Fifteen patients
(32.6%) in the current study had ECOG PS 0-1 and no PVT, and
their median TTP and OS were, respectively, 3.1 months (95% CI,
1.8 to 4.3 months) and 14.5 months (95% CI, 10.5 to 18.5 months),
Table 5. Hematologic and non-hematologic toxicity per patient in
each cisplatin-based combination
No. (%) Doxorubicin Fluoropyrimidine Gemcitabine
Hematologic 
Leukopenia 3 (30) 1 (3.1) 2 (50)
Neutropenia 4 (40) 7 (21.9) 3 (75)
Anemia 0 (0) 5 (15.6) 0 (0)
Thrombocytopenia 0 (0) 3 (9.4) 2 (50)
Non-hematologic
Elevated hepatic  0 (0) 10 (31.2) 1 (25)
aminotransferase
Jaundice 0 (0) 5 (15.6) 3 (75)Nae Yu Kim, et al_Cisplatin-Based Combination Chemotherapy for Hepatocellular Carcinoma
which compares favorably with sorafenib data in an Asian trial (3).
On the other hand, six patients (13%) with ECOG PS 2 and PVT in
the current study had a very poor prognosis and could have been
spared the toxicities of the cisplatin-based combination chemo-
therapy, if patient selection had been based on the above prognostic
factors prior to commencing chemotherapy.
The limitations of our study include its retrospective nature. In
addition, the selection of the chemotherapy regimen was not randomly
assigned, but rather decided based on physician and patient pre-
ference, which could have led to biased results. Furthermore, the
small sample size might have contributed to a lack of power in com-
paring the different chemotherapy regimens with regard to their
toxicity, efficacy, and prognostic value. 
Despite these limitations, our study confirmed the poor prognosis
and efficacy of cisplatin-based combination chemotherapy in
patients with advanced HCC in a real world setting. Our data suggest
that selection of candidates for cisplatin-based combination chemo-
therapy based on prognostic factors - ECOG PS, and presence of
PVT- would benefit select patients with advanced HCC, while sparing
the others the unnecessary toxicities of combination chemotherapy.
Careful classification of patients according to these prognostic varia-
bles should be part of the study design of future investigations of
HCC chemotherapies.
Conclusion
Cisplatin-based combination chemotherapy in patients with
advanced HCC showed a short TTP and a low response rate regar-
dless of the chemotherapy regimen used. Systemic chemotherapy in
patients with advanced HCC has limitations, however. Patients with
a good ECOG performance status and absence of portal vein throm-
bosis had a longer TTP and OS, and therefore can be considered as
good candidates for cisplatin-based combination chemotherapy. 
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